U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07791199) titled 'Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers' on Aug. 25.
Brief Summary: This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjogren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.
Study Start Date: Sept. 02
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Sjogren's Disease
Psoriasis
Psoriatic Arthritis
Intervention:
DRUG: Deucravacitinib
Specified dose on specifie...